189 related articles for article (PubMed ID: 10416040)
1. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.
Shults CW; Haas RH; Beal MF
Biofactors; 1999; 9(2-4):267-72. PubMed ID: 10416040
[TBL] [Abstract][Full Text] [Related]
2. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
3. Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Götz ME; Gerstner A; Harth R; Dirr A; Janetzky B; Kuhn W; Riederer P; Gerlach M
J Neural Transm (Vienna); 2000; 107(1):41-8. PubMed ID: 10809402
[TBL] [Abstract][Full Text] [Related]
4. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases.
Beal MF
Biofactors; 1999; 9(2-4):261-6. PubMed ID: 10416039
[TBL] [Abstract][Full Text] [Related]
5. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients.
Shults CW; Beal MF; Fontaine D; Nakano K; Haas RH
Neurology; 1998 Mar; 50(3):793-5. PubMed ID: 9521279
[TBL] [Abstract][Full Text] [Related]
6. Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.
Sikorska M; Lanthier P; Miller H; Beyers M; Sodja C; Zurakowski B; Gangaraju S; Pandey S; Sandhu JK
Neurobiol Aging; 2014 Oct; 35(10):2329-46. PubMed ID: 24775711
[TBL] [Abstract][Full Text] [Related]
7. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice.
Beal MF; Matthews RT; Tieleman A; Shults CW
Brain Res; 1998 Feb; 783(1):109-14. PubMed ID: 9479058
[TBL] [Abstract][Full Text] [Related]
8. Coenzyme Q10 as a possible treatment for neurodegenerative diseases.
Beal MF
Free Radic Res; 2002 Apr; 36(4):455-60. PubMed ID: 12069110
[TBL] [Abstract][Full Text] [Related]
9. Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptine.
Battino M; Littarru GP; Gorini A; Villa RF
Neurochem Res; 1996 Dec; 21(12):1505-14. PubMed ID: 8953566
[TBL] [Abstract][Full Text] [Related]
10. [An alternative medical approach for the neuroprotective therapy to slow the progression of Parkinson's disease].
Muroyama A
Yakugaku Zasshi; 2013; 133(8):849-56. PubMed ID: 23903224
[TBL] [Abstract][Full Text] [Related]
11. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.
Shults CW; Haas RH; Passov D; Beal MF
Ann Neurol; 1997 Aug; 42(2):261-4. PubMed ID: 9266740
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic role of coenzyme Q(10) in Parkinson's disease.
Shults CW
Pharmacol Ther; 2005 Jul; 107(1):120-30. PubMed ID: 15963354
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of Oxidative Damage by Coenzyme Q
Gupta BK; Kumar S; Kaur H; Ali J; Baboota S
Rejuvenation Res; 2018 Jun; 21(3):232-248. PubMed ID: 28844183
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
Cleren C; Yang L; Lorenzo B; Calingasan NY; Schomer A; Sireci A; Wille EJ; Beal MF
J Neurochem; 2008 Mar; 104(6):1613-21. PubMed ID: 17973981
[TBL] [Abstract][Full Text] [Related]
15. [Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?].
Storch A
Nervenarzt; 2007 Dec; 78(12):1378-82. PubMed ID: 17508194
[TBL] [Abstract][Full Text] [Related]
16. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic.
Horstink MW; van Engelen BG
Arch Neurol; 2003 Aug; 60(8):1170-2; author reply 1172-3. PubMed ID: 12925381
[No Abstract] [Full Text] [Related]
17. Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
Negida A; Menshawy A; El Ashal G; Elfouly Y; Hani Y; Hegazy Y; El Ghonimy S; Fouda S; Rashad Y
CNS Neurol Disord Drug Targets; 2016; 15(1):45-53. PubMed ID: 26553164
[TBL] [Abstract][Full Text] [Related]
18. Coenzyme Q10: a review of its promise as a neuroprotectant.
Young AJ; Johnson S; Steffens DC; Doraiswamy PM
CNS Spectr; 2007 Jan; 12(1):62-8. PubMed ID: 17192765
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria, oxidative damage, and inflammation in Parkinson's disease.
Beal MF
Ann N Y Acad Sci; 2003 Jun; 991():120-31. PubMed ID: 12846981
[TBL] [Abstract][Full Text] [Related]
20. Coenzyme Q10 in early Parkinson disease.
Hunter DA
Arch Neurol; 2003 Aug; 60(8):1170; author reply 1172-3. PubMed ID: 12925382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
